Novo Nordisk Cuts Ozempic and Wegovy Prices Up to 50% Pressuring Eli Lilly
Novo Nordisk will cut U.S. list prices of Ozempic and Wegovy by up to 50%, targeting steeper discounts on key GLP-1 therapies. The move sent both Novo Nordisk and Eli Lilly shares lower as investors assess intensified competition and potential margin pressure.
1. Price Cut Details
Novo Nordisk announced U.S. list-price reductions of up to 50% on its leading GLP-1 treatments Ozempic for diabetes and Wegovy for weight loss. The cuts aim to bolster demand in an increasingly competitive market crowded by rival therapies and payor pushback on high costs.
2. Market Reaction and Implications
Shares of both Novo Nordisk and Eli Lilly dipped following the announcement as investors weighed the likelihood of margin erosion across diabetes and obesity franchises. Eli Lilly may face pressure to adjust pricing or boost promotional efforts for its Mounjaro GLP-1 drug to defend market share and revenue growth.